NextCure (NASDAQ:NXTC) Stock Rating Lowered by Zacks Research

NextCure (NASDAQ:NXTC) was downgraded by equities research analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a note issued to investors on Wednesday,Zacks.com reports.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of NextCure in a research note on Monday, April 27th. Three research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat, NextCure has an average rating of “Hold” and an average target price of $23.00.

NextCure Stock Down 5.0%

NextCure stock opened at $10.18 on Wednesday. NextCure has a 52 week low of $4.44 and a 52 week high of $15.74. The company’s 50 day moving average price is $11.31 and its two-hundred day moving average price is $11.67. The stock has a market cap of $36.75 million, a P/E ratio of -0.51 and a beta of 1.43.

NextCure (NASDAQ:NXTC) last posted its earnings results on Thursday, May 7th. The company reported ($1.87) EPS for the quarter, topping the consensus estimate of ($2.10) by $0.23. On average, equities analysts anticipate that NextCure will post -8.98 EPS for the current year.

Institutional Investors Weigh In On NextCure

A number of hedge funds have recently modified their holdings of NXTC. Marshall Wace LLP bought a new stake in shares of NextCure in the 4th quarter worth approximately $160,000. Millennium Management LLC bought a new stake in shares of NextCure in the 4th quarter worth approximately $185,000. Geode Capital Management LLC raised its holdings in shares of NextCure by 18.6% in the 4th quarter. Geode Capital Management LLC now owns 23,157 shares of the company’s stock worth $329,000 after purchasing an additional 3,636 shares during the period. Cable Car Capital LP raised its holdings in shares of NextCure by 13.1% in the 2nd quarter. Cable Car Capital LP now owns 758,141 shares of the company’s stock worth $349,000 after purchasing an additional 88,040 shares during the period. Finally, Renaissance Technologies LLC raised its stake in NextCure by 18.7% in the 4th quarter. Renaissance Technologies LLC now owns 33,634 shares of the company’s stock valued at $477,000 after acquiring an additional 5,300 shares during the period. Institutional investors own 42.65% of the company’s stock.

NextCure Company Profile

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.